Skip to main content
OpenTrials
Completed

NCT Number: NCT01625481

Seal-V Safety and Performance Study

The purpose of this study is to further assess the safety and performance of Seal-V as an adjunct to standard surgical procedure for achieving hemostasis in patients undergoing peripheral vascular reconstruction surgeries using synthetic grafts.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Department of Vascular Surgery, Bnai-Zion Medical Center, Haifa, Israel

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female of >18 years of age
  • Signed Informed Consent
  • Patients requiring vascular reconstruction surgeries using synthetic (such as PTFE, Dacron) or autologous (such as native veins) grafts, including the following:
  • Peripheral bypass surgeries, such as arterio-arterial bypasses [including: axillo-(bi)femoral, ilio-(bi)femoral, femoro-femoral, ilio-popliteal, femoro-popliteal (including below knee), femoro-tibial vessel bypass]
  • Arteriovenous (AV) dialysis access shunt in the upper or lower extremity
  • Patients able and willing to complete all follow-up visits

Exclusion criteria

  • Vascular surgery other than peripheral bypass surgeries and arteriovenous (AV) dialysis access shunt procedures as described above
  • Reoperation at the same treatment site
  • Known sensitivity to device materials, such as indigo carmine dye or alginate
  • Pregnant or lactating women
  • Systemic infection
  • Participation in another clinical trial or treatment with any investigational agent in past 30 days
  • Congenital coagulation disorders (e.g., thrombocytopenia [<100,000 platelet count], thromboasthenia, hemophilia, or von Willebrand disease)
  • Severe congenital or acquired immunodeficiency (e.g., HIV infection or long term treatment with immunosuppressive drugs)
  • Prior radiation therapy to the operating field

Intraoperative Exclusion Criteria:

  • Major intraoperative complications that require resuscitation or deviation from the planned surgical procedure
  • Intraoperative change in planned surgical procedure that results in the patient no longer meeting preoperative inclusion and/or exclusion criteria
  • Local infection at the operating field

Treatment and study plan

Seal-V

Device

Seal-V is applied adjunctively to cover the suture lines.

Other names: SEAlantis Vascular WP2(A)

Primary outcomes

  1. TTH, Time to Hemostasis

    Time frame: Perioperative; within 10 minutes after clamp release

    Duration from the point at which circulation is restored to the graft/artery until bleeding ceases at the treatment site

Secondary outcomes

  1. Successful cessation of bleeding at a treatment site

    Time frame: Perioperative; within 10 minutes after clamp release

  2. Intraoperative blood loss

    Time frame: Perioperative

    Measured by weighing the surgical swabs used only in the application area and used from the time Seal-V was applied until hemostasis

  3. Incidence of successful deployment of the Seal-V device

    Time frame: Perioperative

Sponsors and collaborators

Lead sponsor

Sealantis Ltd.

Industry

Registry information

Official study title

Prospective, Single Arm, Open Label, Non-randomized Study to Evaluate The Safety and Performance of The Seal-V System

Important dates

Study start
2012
Primary completion
2013
Study completion
2014
First posted
Jun 21, 2012
Registry last updated
May 28, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.